Nature Biotechnology, Published online: 25 June 2026; doi:10.1038/s41587-026-03139-8
This Comment outlines molecular and technical considerations for developing mechanistically grounded virtual immune cell models.
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling
Nature Medicine, Published online: 25 June 2026; doi:10.1038/s41591-026-04481-9
Mass-spectrometry-based metabolomic analysis of plasma samples from multiple cohorts of patients treated with immunotherapy across five distinct tumor types, followed by machine learning enabled identification of metabolic signatures, as well as functional exploration, reveals association of increased plasma histidine levels with prolonged survival and its potential for therapeutic intervention.
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial
Nature Medicine, Published online: 25 June 2026; doi:10.1038/s41591-026-04453-z
In the randomized phase 2 Neo-CheckRay trial, patients with early-stage ER+HER2− breast cancer received neoadjuvant immune-modulating stereotactic body radiation therapy with or without durvalumab, and with or without the anti-CD73 antibody oleclumab, leading to encouraging clinical responses when durvalumab was added including in patients with PD-L1-negative tumors.
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial
Nature Medicine, Published online: 25 June 2026; doi:10.1038/s41591-026-04471-x
In the ongoing phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5) trial in patients with transplant-eligible, newly diagnosed multiple myeloma, induction with the BCMA×CD3 bispecific engager teclistamab in combination with daratumumab plus lenalidomide, with or without bortezomib, had a similar toxicity profile to other bispecific regimens with an encouraging and deep response rate.
Learning shapes neural geometry in the primate prefrontal cortex
Nature Neuroscience, Published online: 25 June 2026; doi:10.1038/s41593-026-02333-w
Learning transforms prefrontal cortex activity from flexible, high-dimensional representations into compact, task-relevant and abstract codes, enabling efficient generalization of learned rules to new stimuli and contexts.
DBS: from neuromodulation to neuroremodelling
Nature Neuroscience, Published online: 25 June 2026; doi:10.1038/s41593-026-02347-4
Deep-brain stimulation (DBS) treats movement and neuropsychiatric disorders through mechanisms that remain unclear. Two studies that combine longitudinal neuroimaging, stimulation experiments and tissue-level analysis show that the effects of DBS evolve in space and time, demonstrating acute effects on network activity as well as providing insights into chronic effects that reshape the networks it engages.
Human hippocampal ripples tune cortical responses based on predicted uncertainty
Nature Neuroscience, Published online: 25 June 2026; doi:10.1038/s41593-026-02345-6
Using direct recordings from the human brain, Frank et al. show that hippocampal ripples increase ahead of unpredictable events and tune the visual cortex to respond faster and more strongly to surprising stimuli that follow.
InduPro Licenses Lonza’s Linker Payload Technologies and Bioconjugation Platforms
Lonza and InduPro signed a licensing agreement to support the advancement of innovative antibody–drug conjugate (ADC) therapies. According to Lonza officials, the company, through one of its affiliated companies, will grant InduPro a non-exclusive, worldwide license to its proprietary GlycoConnect®, HydraSpace® and linker-payload technologies. The technologies, which will be applied to the development of ADCs targeting up to two oncology antigens, are intended to support the advancement of highly targeted cancer therapies.
InduPro will combine its proprietary bispecific antibody capabilities with Lonza’s ADC platform. By leveraging these complementary technologies, the companies aim to develop differentiated therapeutic approaches designed to address complex diseases such as cancer, where precision targeting and efficacy remain critically important, notes Jan Vertommen, vice president of commercial development, advanced synthesis, Lonza.
“By combining our expertise in bioconjugation technologies and manufacturing with InduPro’s innovative proximity guided antibody platform, we reinforce our commitment to enabling our licensing partners and supporting the advancement of next-generation ADC programs,” says Vertommen.
“This agreement represents an important step in advancing our pipeline of proximity-driven bispecific ADCs,” adds Prakash Raman, CEO, InduPro. “By combining InduPro’s ability to identify novel, disease-specific co-target pairs with Lonza’s industry-leading ADC technologies, we aim to develop differentiated, first-in-class therapeutics that improve selectivity, expand therapeutic windows, and ultimately deliver better outcomes for patients with hard-to-treat tumors.”
The post InduPro Licenses Lonza’s Linker Payload Technologies and Bioconjugation Platforms appeared first on GEN – Genetic Engineering and Biotechnology News.
STAT+: FDA gives generative AI in radiology two breakthrough designation nods
The Food and Drug Administration has granted breakthrough designation to two devices that use generative AI to interpret chest X-rays and draft the radiology reports typically written by human radiologists.
Machine learning systems have long analyzed images like X-rays and CT scans. But more recently, large vision language models have ushered in a new capability. Instead of highlighting a spot for a radiologist to review and write up, generative AI can process the entire image and draft many of its findings for a radiologist to review — a technological advancement that is challenging traditional validation and regulatory frameworks.
In March, one breakthrough designation went to Cognita, a Stanford researcher-founded startup acquired late last year by the large radiology practice Radiology Partners. Radiology AI company Aidoc announced its own breakthrough designation Thursday for a tool called First Read, specifically when it is used to detect and describe four life-threatening findings.
Another roadblock for DOJ campaign against trans health
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning and happy Thursday. Let’s get right to it.